Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma.
作者信息
Yang Fan, Shi Hui, Xu Teng, Liu Rui, Lei Yang, Li Ruiting, Deng Biping, Wu Tong, Ke Xiaoyan, Hu Kai
机构信息
Department of Adult Lymphoma, Beijing Boren Hospital, Beijing, China.
Cytology Laboratory, Beijing Boren Hospital, Beijing, China.
出版信息
Bone Marrow Transplant. 2023 Apr;58(4):440-442. doi: 10.1038/s41409-022-01903-3. Epub 2022 Dec 22.
Abstract
摘要
相似文献
1
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma.异基因干细胞移植联合包括供体来源的嵌合抗原受体T细胞（CAR-T细胞）的预处理方案用于难治性/复发性B细胞淋巴瘤。
Bone Marrow Transplant. 2023 Apr;58(4):440-442. doi: 10.1038/s41409-022-01903-3. Epub 2022 Dec 22.
2
Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.供体来源的 CAR-T 细胞作为减轻强度预处理方案，用于治疗复发/难治性急性淋巴细胞白血病的单倍体相合干细胞移植：病例报告及文献复习。
J Immunother. 2018 Jul/Aug;41(6):306-311. doi: 10.1097/CJI.0000000000000233.
3
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.预处理化疗联合 CD19 靶向嵌合抗原受体 T 细胞治疗复发/难治性 CLL 的安全性和耐受性。
JCI Insight. 2019 Apr 2;5(9):122627. doi: 10.1172/jci.insight.122627.
4
CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.嵌合抗原受体T细胞（CAR-T）与异基因造血干细胞移植治疗复发/难治性B细胞急性淋巴细胞白血病
Immunotherapy. 2017 Oct;9(13):1115-1125. doi: 10.2217/imt-2017-0072.
5
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.自体干细胞移植作为桥接治疗，随后使用CD19嵌合抗原受体T细胞治疗复发难治性大B细胞淋巴瘤。
Bone Marrow Transplant. 2022 May;57(5):837-839. doi: 10.1038/s41409-022-01632-7. Epub 2022 Mar 8.
6
Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.异基因供体来源的抗 CD19 CAR T 细胞是异基因造血干细胞移植后复发/难治性 B-ALL 的一种有前途的治疗方法。
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):610-616. doi: 10.1016/j.clml.2020.04.007. Epub 2020 Apr 18.
7
Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.嵌合抗原受体 T 细胞在异基因造血干细胞移植中的应用。
Immunotherapy. 2019 Jan;11(1):37-44. doi: 10.2217/imt-2018-0089.
8
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.异基因干细胞移植治疗复发/难治性B细胞淋巴瘤：一项多中心II期前瞻性试验的结果，该试验在减低剂量预处理方案中纳入了利妥昔单抗
Biol Blood Marrow Transplant. 2017 Jul;23(7):1102-1109. doi: 10.1016/j.bbmt.2017.03.031. Epub 2017 Apr 5.
9
Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph B cell acute lymphoblastic leukemia.病例报告：在复发/难治性费城染色体阳性 B 细胞急性淋巴细胞白血病中，使用 CAR-T 细胞治疗作为预处理方案，成功进行异基因造血干细胞移植。
Front Immunol. 2022 Sep 26;13:965932. doi: 10.3389/fimmu.2022.965932. eCollection 2022.
10
Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.使用淋巴细胞清除而非骨髓清除预处理方案进行异基因干细胞移植治疗复发或难治性淋巴瘤。
Hematol Oncol. 2017 Mar;35(1):17-24. doi: 10.1002/hon.2201. Epub 2015 Mar 18.
本文引用的文献
1
'Off-the-shelf' allogeneic CAR T cells: development and challenges.现成的异体嵌合抗原受体 T 细胞：开发与挑战。
Nat Rev Drug Discov. 2020 Mar;19(3):185-199. doi: 10.1038/s41573-019-0051-2. Epub 2020 Jan 3.
2
Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group.异基因干细胞移植治疗弥漫性大 B 细胞淋巴瘤的结果：来自京都干细胞移植组的一项多中心研究。
Ann Hematol. 2019 Dec;98(12):2815-2823. doi: 10.1007/s00277-019-03835-3. Epub 2019 Nov 12.
3
Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.嵌合抗原受体T细胞疗法治疗B细胞非霍奇金淋巴瘤：机遇与挑战
Drugs Context. 2019 Feb 13;8:212567. doi: 10.7573/dic.212567. eCollection 2019.
4
Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤的造血细胞移植：当前的争议与进展
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):277-284. doi: 10.1016/j.hemonc.2017.05.004. Epub 2017 Jun 13.
5
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.异基因造血细胞移植作为非霍奇金淋巴瘤患者的治愈性疗法：在老年患者中的应用日益成功。
Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-1551. doi: 10.1016/j.bbmt.2016.04.019. Epub 2016 Apr 27.
6
Breakthrough therapies in B-cell non-Hodgkin lymphoma.B 细胞非霍奇金淋巴瘤的突破性疗法。
Ann Oncol. 2016 May;27(5):778-87. doi: 10.1093/annonc/mdw029. Epub 2016 Jan 22.
7
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.伴有或不伴有利妥昔单抗的 CHOP 样化疗治疗预后良好的弥漫性大 B 细胞淋巴瘤的年轻患者：MabThera 国际试验（MInT）组的一项开放性随机研究的 6 年结果。
Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.
8
Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.抗胸腺细胞球蛋白和粒细胞集落刺激因子动员的骨髓在血液系统恶性肿瘤患者异基因移植中的作用。
Biol Blood Marrow Transplant. 2009 Feb;15(2):266-73. doi: 10.1016/j.bbmt.2008.11.029.
9
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.采用降低强度预处理后进行造血细胞同种异体移植，可使高危血液系统恶性肿瘤患者实现临床和分子缓解。
Blood. 2002 Jan 1;99(1):75-82. doi: 10.1182/blood.v99.1.75.
10
Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation.自体移植后复发患者的异基因骨髓移植。
Bone Marrow Transplant. 1997 Nov;20(10):859-63. doi: 10.1038/sj.bmt.1700989.
Zotero 插件